Search
BIO 2026: The gout market is currently served by two extremes, generic allopurinol in first line and a therapy for extreme refractory cases. Crystalys' experienced team wants to change that
CEO James Mackay describes the company's therapy, dotinurad, which has been approved in Japan since 2020. It is a URAT1 inhibitor, a mechanism that he and his team are very familiar with. Coverage brought to you by
1 day ago
.png){kind=logo}